| scholarly article | Q13442814 |
| P356 | DOI | 10.1182/BLOOD.V99.5.1536 |
| P698 | PubMed publication ID | 11861265 |
| P50 | author | Nicola Gökbuget | Q47158585 |
| Harald E Rieder | Q53134919 | ||
| Dieter Hoelzer | Q15437636 | ||
| P2093 | author name string | Eckhard Thiel | |
| Axel Heyll | |||
| Claus R Bartram | |||
| Johannes W G Janssen | |||
| Bart Janssen | |||
| Jürgen Maurer | |||
| Gerd Munzert | |||
| Christa Fonatsch | |||
| Beate Gleissner | |||
| Dimitris Voliotis | |||
| Joachim Beck | |||
| Thomas Lipp | |||
| German Multicenter Trials of Adult Acute Lymphoblastic Leukemia Study Group | |||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | multicenter clinical trial | Q6934595 |
| lymphoblastic leukemia | Q18553852 | ||
| leukemia | Q29496 | ||
| P304 | page(s) | 1536-1543 | |
| P577 | publication date | 2002-03-01 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis. | |
| P478 | volume | 99 |
| Q38674589 | A review of CD19-targeted immunotherapies for relapsed or refractory acute lymphoblastic leukemia. |
| Q56722375 | Acute lymphoblastic leukaemia |
| Q35894965 | Acute lymphoblastic leukaemia in elderly patients: biological characteristics and therapeutic approaches |
| Q38023709 | Acute lymphoblastic leukemia expressing b3a2 (p210), e1a2 (p190), and variant e1a2 BCR-ABL transcripts: a case report and review of the literature |
| Q35331684 | Acute lymphoblastic leukemia in elderly patients: a single institution's experience |
| Q53404353 | Adult precursor B lymphoblastic leukemia in Shanghai, China: characterization of phenotype, cytogenetics and outcome for 137 consecutive cases. |
| Q36600241 | Advances and potential treatment for Philadelphia chromosome-positive adult acute lymphoid leukaemia |
| Q61449792 | Advances in biology of acute lymphoblastic leukemia (ALL) and therapeutic implications |
| Q38698520 | Advances in therapy for Philadelphia-positive acute lymphoblastic leukaemia of childhood and adolescence |
| Q36984852 | Allogeneic haematopoietic stem cell transplant in Philadelphia-positive acute lymphoblastic leukaemia |
| Q34233335 | An adult B-cell precursor acute lymphoblastic leukemia with multiple secondary cytogenetic aberrations |
| Q34116091 | An automated analysis of highly complex flow cytometry-based proteomic data. |
| Q36289034 | Ancillary techniques in bone marrow pathology: molecular diagnostics on bone marrow trephine biopsies |
| Q37530579 | Anti-CD19 chimeric antigen receptor T-cell therapy for adult Philadelphia chromosome-positive acute lymphoblastic leukemia: Two case reports |
| Q55027080 | Atypical BCR-ABL1 fusion transcripts in adult B-acute lymphoblastic leukemia, including a novel fusion transcript-e8a1. |
| Q37003563 | BCR-ABL fusion transcript types and levels and their interaction with secondary genetic changes in determining the phenotype of Philadelphia chromosome-positive leukemias |
| Q57734316 | BCR–ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros |
| Q39503233 | Bioimaging analysis of nuclear factor-κB activity in Philadelphia chromosome-positive acute lymphoblastic leukemia cells reveals its synergistic upregulation by tumor necrosis factor-α-stimulated changes to the microenvironment |
| Q51041845 | CD25 Expression in B Lymphoblastic Leukemia/Lymphoma Predicts t(9;22)(q34;q11)/Philadelphia Chromosome Translocation (Ph) and Is Associated With Residual Disease in Ph-Negative Patients. |
| Q99567329 | CD9 knockdown suppresses cell proliferation, adhesion, migration and invasion, while promoting apoptosis and the efficacy of chemotherapeutic drugs and imatinib in Ph+ ALL SUP‑B15 cells |
| Q39798534 | Characterization of B- and T-lineage acute lymphoblastic leukemia by integrated analysis of MicroRNA and mRNA expression profiles. |
| Q51592957 | Children and adults with acute lymphoblastic leukaemia have similar gene expression profiles. |
| Q36788127 | Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance |
| Q35111716 | Clinical Applications of BCR-ABL Molecular Testing in Acute Leukemia |
| Q43168908 | Clinical characteristics and outcomes of adults with Philadelphia chromosome positive and/or bcr-abl positive acute lymphoblastic leukemia: a single center study from China |
| Q46611126 | Clinical effect of imatinib added to intensive combination chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia |
| Q33632230 | Clinical features and prognostic implications of TCF3-PBX1 and ETV6-RUNX1 in adult acute lymphoblastic leukemia |
| Q42256587 | Clinical outcome of hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL): experience from a single institution |
| Q37273171 | Clinico-biological features of 5202 patients with acute lymphoblastic leukemia enrolled in the Italian AIEOP and GIMEMA protocols and stratified in age cohorts |
| Q45204180 | Combination of imatinib and cytarabine for the treatment of Philadelphia chromosome positive acute lymphoblastic leukemia |
| Q33587563 | Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial |
| Q39366299 | Continuing challenges and current issues in acute lymphoblastic leukemia. |
| Q38194585 | Current and future management of Ph/BCR-ABL positive ALL. |
| Q47710825 | Current paradigms in the management of Philadelphia chromosome positive acute lymphoblastic leukemia in adults |
| Q37650203 | Current treatment options for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia |
| Q47291002 | Cytogenetic testing for therapeutic indication in cancer |
| Q34304230 | Cytogenetics in acute leukemia |
| Q59547714 | Deletions on der(9) chromosome in adult Ph-positive acute lymphoblastic leukemia occur with a frequency similar to that observed in chronic myeloid leukemia |
| Q35553341 | Developmental origins and impact of BCR-ABL1 fusion and IKZF1 deletions in monozygotic twins with Ph+ acute lymphoblastic leukemia |
| Q26824387 | Diagnosis and subclassification of acute lymphoblastic leukemia |
| Q61755942 | Diagnostic Applications of Nuclear Medicine: Leukemias |
| Q92158098 | Diagnostic and treatment of adult Philadelphia chromosome-positive acute lymphoblastic leukemia |
| Q37594153 | ETS-related gene is a novel prognostic factor in childhood acute lymphoblastic leukemia |
| Q44598654 | Efficacy and safety of imatinib mesylate (Glivec) in combination with interferon-alpha (IFN-alpha) in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL). |
| Q52907170 | Expression of interleukin 15 in primary adult acute lymphoblastic leukemia. |
| Q40571894 | Expression of the human homologue of rat NG2 in adult acute lymphoblastic leukemia: close association with MLL rearrangement and a CD10(-)/CD24(-)/CD65s(+)/CD15(+) B-cell phenotype. |
| Q37319942 | Failure of CDKN2A/B (INK4A/B-ARF)-mediated tumor suppression and resistance to targeted therapy in acute lymphoblastic leukemia induced by BCR-ABL. |
| Q52563633 | Final analysis of the JALSG Ph+ALL202 study: tyrosine kinase inhibitor-combined chemotherapy for Ph+ALL. |
| Q34977308 | Flow cytometric immunobead assay for the detection of BCR-ABL fusion proteins in leukemia patients. |
| Q42141317 | Frequency of p190 and p210 BCR-ABL rearrangements and survival in Brazilian adult patients with acute lymphoblastic leukemia |
| Q60203892 | Genetic heterogeneity of BCR/ABL+ adult B-cell precursor acute lymphoblastic leukemia: impact on the clinical, biological and immunophenotypical disease characteristics |
| Q37401075 | Genome-wide profiling of genetic alterations in acute lymphoblastic leukemia: recent insights and future directions. |
| Q37782546 | Genomic profiling of high-risk acute lymphoblastic leukemia. |
| Q36923835 | Heterologous Vaccination and Checkpoint Blockade Synergize To Induce Antileukemia Immunity. |
| Q39010282 | Identification of heat shock protein 32 (Hsp32) as a novel target in acute lymphoblastic leukemia |
| Q39751939 | Illegitimate RAG-mediated recombination events are involved in IKZF1 Δ3-6 deletion in BCR-ABL1 lymphoblastic leukaemia |
| Q36634604 | Imatinib combined chemotherapy for Philadelphia chromosome-positive acute lymphoblastic leukemia: major challenges in current practice |
| Q58414406 | Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) |
| Q35904266 | Imatinib mesylate therapy in patients of chronic myeloid leukemia with Philadelphia chromosome positive: an experience from eastern India |
| Q36108349 | Impact of Additional Cytogenetic Abnormalities in Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation |
| Q36478476 | Impact of cytogenetics on the outcome of adult acute lymphoblastic leukemia: results of Southwest Oncology Group 9400 study |
| Q34497738 | In vitro validation of bioluminescent monitoring of disease progression and therapeutic response in leukaemia model animals |
| Q99628527 | Is Less More? Intensive Versus Non-Intensive Approach to Adults with Ph+ ALL |
| Q35082503 | LMO2 expression reflects the different stages of blast maturation and genetic features in B-cell acute lymphoblastic leukemia and predicts clinical outcome. |
| Q38423781 | Long-term follow-up of imatinib plus combination chemotherapy in patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia |
| Q46236668 | Long-term outcome of L86 and L97 protocols for adult acute lymphoblastic leukemia |
| Q44492984 | Mechanisms of Bcr-Abl-mediated NF-kappaB/Rel activation |
| Q33606018 | Murine models of acute leukemia: important tools in current pediatric leukemia research |
| Q34734850 | Mutation-specific control of BCR-ABL T315I positive leukemia with a recombinant yeast-based therapeutic vaccine in a murine model |
| Q81093828 | Myeloablative allogeneic hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia in adults: significant roles of total body irradiation and chronic graft-versus-host disease |
| Q37810095 | New mechanisms of resistance in Philadelphia chromosome acute lymphoblastic leukemia |
| Q54342246 | Outcome after HSCT in Philadelphia chromosome positive acute lymphoblastic leukemia in Sweden: a population-based study. |
| Q93112971 | Outcome of Philadelphia Positive Acute Lymphoblastic Leukemia With or Without Allogeneic Stem Cell Transplantation in a Retrospective Study |
| Q41843107 | Phase II trial of hyper CVAD and dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia |
| Q55263277 | Phenotyping and Target Expression Profiling of CD34+/CD38- and CD34+/CD38+ Stem- and Progenitor cells in Acute Lymphoblastic Leukemia. |
| Q37613888 | Philadelphia chromosome-positive acute lymphoblastic leukemia |
| Q39055512 | Philadelphia chromosome-positive acute lymphoblastic leukemia: 8 years' experience from a tertiary care center in India |
| Q37862648 | Philadelphia chromosome-positive acute lymphoblastic leukemia: current treatment and future perspectives |
| Q36562207 | Philadelphia chromosome-positive acute lymphoblastic leukemia: impact of imatinib treatment on remission induction and allogeneic stem cell transplantation |
| Q38044901 | Philadelphia chromosome-positive leukemia stem cells in acute lymphoblastic leukemia and tyrosine kinase inhibitor therapy |
| Q36228062 | Philadelphia positive acute lymphoblastic leukaemia of childhood |
| Q38016343 | Philadelphia-positive acute lymphoblastic leukemia: current treatment options |
| Q40376516 | Placenta growth factor stimulates the growth of Philadelphia chromosome positive acute lymphoblastic leukemia cells by both autocrine and paracrine pathways |
| Q35875306 | Plasma cell myeloma and leukemia |
| Q54643257 | Pre-transplant imatinib-based therapy improves the outcome of allogeneic hematopoietic stem cell transplantation for BCR-ABL-positive acute lymphoblastic leukemia. |
| Q42183096 | Prognostic factors influencing clinical outcome of allogeneic hematopoietic stem cell transplantation following imatinib-based therapy in BCR-ABL-positive ALL |
| Q61803967 | Prognostic implications of additional genomic lesions in adult Philadelphia chromosome-positive acute lymphoblastic leukemia |
| Q41299717 | Prognostic significance of immunophenotypic and karyotypic features of Philadelphia positive B-lymphoblastic leukemia in the era of tyrosine kinase inhibitors |
| Q61053580 | Prospective multicentric molecular study for poor prognosis fusion transcripts at diagnosis in adult B-lineage ALL patients: the LALA 94 experience |
| Q33412662 | Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International |
| Q39690602 | Protein kinase gene expression profiling and in vitro functional experiments identify novel potential therapeutic targets in adult acute lymphoblastic leukemia |
| Q92276422 | Recent advances in the biology and treatment of B-cell acute lymphoblastic leukemia |
| Q37353919 | Recent advances in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia |
| Q78317063 | Recent publications in hematology oncology |
| Q37194503 | Recurrent gene fusions in prostate cancer |
| Q99235920 | Recurrent genetic abnormalities detected by FISH in adult B ALL and association with hematological parameters |
| Q44582795 | Serial minimal residual disease (MRD) analysis as a predictor of response duration in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) during imatinib treatment |
| Q45296433 | Significant reduction of the hybrid BCR/ABL transcripts after induction and consolidation therapy is a powerful predictor of treatment response in adult Philadelphia-positive acute lymphoblastic leukemia. |
| Q35789809 | Single monochrome real-time RT-PCR assay for identification, quantification, and breakpoint cluster region determination of t(9;22) transcripts |
| Q92276397 | Spotlight on ponatinib in the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia: patient selection and perspectives |
| Q44100980 | Stable engraftment after a conditioning regimen with fludarabine and melphalan for bone marrow transplantation from an unrelated donor |
| Q45924497 | Stable non-transforming minimal residual disease in Philadelphia chromosome positive acute lymphoblastic leukemia after autologous transplantation: origin from neoplastic yet 'pre-leukemic' stem cells? |
| Q35561038 | Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. |
| Q33395138 | Subdural hematomas in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving imatinib mesylate in conjunction with systemic and intrathecal chemotherapy |
| Q48571436 | Targeting CDK6 and BCL2 exploits the "MYB addiction" of Ph+ acute lymphoblastic leukemia |
| Q57461994 | Targeting STAT5 or STAT5-Regulated Pathways Suppresses Leukemogenesis of Ph+ Acute Lymphoblastic Leukemia |
| Q92210851 | The NEDD8-activating enzyme inhibitor MLN4924 induces DNA damage in Ph+ leukemia and sensitizes for ABL kinase inhibitors |
| Q38829019 | The development of agents targeting the BCR-ABL tyrosine kinase as Philadelphia chromosome-positive acute lymphoblastic leukemia treatment |
| Q58924215 | The effect of polymorphisms of gamma-glutamyl hydrolase (GGH) gene on methotrexate-induced toxicity in acute lymphoblastic leukemia |
| Q41840259 | The pan-BCL-2-blocker obatoclax (GX15-070) and the PI3-kinase/mTOR-inhibitor BEZ235 produce cooperative growth-inhibitory effects in ALL cells. |
| Q46562404 | The presence of Philadelphia chromosome does not confer poor prognosis in adult pre-B acute lymphoblastic leukaemia in the tyrosine kinase inhibitor era - a surveillance, epidemiology, and end results database analysis |
| Q37271941 | Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years |
| Q37657483 | Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia |
| Q38087930 | Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia |
| Q41534360 | Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in pregnancy |
| Q37152745 | Treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia |
| Q37738455 | Treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia with imatinib in combination with chemotherapy |
| Q37244701 | Treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia |
| Q43175147 | Tyrosine kinase inhibitors in BCR-ABL positive acute lymphoblastic leukemia |
| Q38739574 | Tyrosine kinase inhibitors in Ph+ acute lymphoblastic leukaemia: facts and perspectives |
| Q30424785 | c-Myb and its target Bmi1 are required for p190BCR/ABL leukemogenesis in mouse and human cells |
Search more.